Biochanin A Mitigates Pressure Overload-Induced Cardiac Hypertrophy Through Modulation of the NF-κB/Cbl-b/NLRP3...

Area of Science:

• Cardiovascular Biology
• Molecular Mechanisms of Disease
• Pharmacology

Background:

• Cardiac hypertrophy is a significant risk factor for heart failure.
• The NLRP3 inflammasome and pyroptosis pathway play a critical role in cardiac remodeling and dysfunction.
• Identifying novel therapeutic agents to target these pathways is crucial for cardiovascular disease treatment.

Purpose of the Study:

• To investigate the protective effects of biochanin A (BCA) against cardiac hypertrophy.
• To elucidate the molecular mechanisms underlying BCA's action, particularly its interaction with the NLRP3 pyroptosis pathway.
• To determine if BCA can reverse pressure overload and AngII-induced cardiac and cardiomyocyte hypertrophy.

Main Methods:

• Utilized animal models of pressure overload-induced cardiac hypertrophy and in vitro AngII-induced cardiomyocyte hypertrophy.
• Analyzed NLRP3 expression and related signaling molecules via western blotting.
• Assessed NLRP3 pathway activity using pyroptosis assays and investigated the role of Cbl-b.

Main Results:

• BCA administration reversed heart dysfunction and attenuated cardiomyocyte hypertrophy in both models.
• BCA mitigated cardiac hypertrophy by targeting the NLRP3 pyroptosis pathway, reducing NLRP3 expression.
• BCA upregulated Cbl-b, enhancing NLRP3 ubiquitination and degradation, and interacted with NF-κB to promote Cbl-b expression.

Conclusions:

• Biochanin A demonstrates protective effects against cardiac hypertrophy.
• BCA's mechanism involves NF-κB interaction, Cbl-b upregulation, and subsequent NLRP3 pyroptosis inhibition.
• BCA emerges as a potential therapeutic candidate for treating cardiac hypertrophy.